Literature DB >> 14517440

Angiogenesis and ophthalmic disease.

A P Adamis1, L P Aiello, R A D'Amato.   

Abstract

Ocular angiogenesis is responsible for the majority of irreversible blindness in the developed world [1]. This debilitating complication affects all age groups and characterizes such diverse and widespread diseases as trachoma, retinopathy of prematurity, diabetic retinopathy, neovascular glaucoma and age-related macular degeneration. Although numerous relatively rare conditions also exhibit ocular angiogenesis, the aim of this review will be to briefly summarize our current knowledge regarding the clinical and laboratory findings of the most epidemiologically significant diseases. We will also describe current concepts regarding the pathogenesis of ocular angiogenesis. In this review the term 'neovascularization', which is more prevalent in the ophthalmic literature, will be used to describe the development of pathological new vessels and should be considered synonymous with 'angiogenesis'.

Entities:  

Year:  1999        PMID: 14517440     DOI: 10.1023/a:1009071601454

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  29 in total

1.  Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).

Authors:  Lihteh Wu; María A Martínez-Castellanos; Hugo Quiroz-Mercado; J Fernando Arevalo; María H Berrocal; Michel E Farah; Mauricio Maia; José A Roca; Francisco J Rodriguez
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-03       Impact factor: 3.117

2.  Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis.

Authors:  Michael I Dorrell; Edith Aguilar; Lea Scheppke; Faith H Barnett; Martin Friedlander
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-08       Impact factor: 11.205

3.  Mesenchymal stem cells improve healing of the cornea after alkali injury.

Authors:  Diamantis Almaliotis; Georgios Koliakos; Eleni Papakonstantinou; Anastasia Komnenou; Angelos Thomas; Spiros Petrakis; Ilias Nakos; Eleni Gounari; Vasileios Karampatakis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-05-23       Impact factor: 3.117

Review 4.  Glycobiology of ocular angiogenesis.

Authors:  Anna I Markowska; Zhiyi Cao; Noorjahan Panjwani
Journal:  Glycobiology       Date:  2014-08-08       Impact factor: 4.313

5.  Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases.

Authors:  Lynn W Maines; Kevin J French; Ellen B Wolpert; David A Antonetti; Charles D Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-11       Impact factor: 4.799

6.  Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascularization in ischemic retinopathy.

Authors:  F Sennlaub; Y Courtois; O Goureau
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

7.  Thrombospondin-1-Based Antiangiogenic Therapy.

Authors:  Jennifer N Sims; Jack Lawler
Journal:  J Ocul Pharmacol Ther       Date:  2015-06-03       Impact factor: 2.671

Review 8.  Diabetic retinopathy and pregnancy.

Authors:  Nicola Pescosolido; Orazio Campagna; Andrea Barbato
Journal:  Int Ophthalmol       Date:  2014-01-31       Impact factor: 2.031

9.  TMP prevents retinal neovascularization and imparts neuroprotection in an oxygen-induced retinopathy model.

Authors:  Xiaoling Liang; Huanjiao Zhou; Yungang Ding; Jie Li; Cheng Yang; Yan Luo; Shiqing Li; Gang Sun; Xulong Liao; Wang Min
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-04-24       Impact factor: 4.799

10.  Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

Authors:  Kazuaki Nishijima; Yin-Shan Ng; Lichun Zhong; John Bradley; William Schubert; Nobuo Jo; Jo Akita; Steven J Samuelsson; Gregory S Robinson; Anthony P Adamis; David T Shima
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.